MyeloTrak

 

Category: *Precision Health & Smart Medical

Exhibitor: MARKER X CO., LTD.

Booth No: N602

 

Characteristic

 

This product won the 2026 National Innovation Award and was selected for the Mayo Clinic and ASU Alliance for Health Care Accelerator!

MarkerX proudly introduces MyeloTrak, a revolutionary solution pioneering its field in Taiwan. By integrating blood sampling with advanced mass spectrometry and big data AI analysis, MyeloTrak significantly enhances the ability to track early recurrence of multiple myeloma. This provides patients with more precise diagnoses, facilitating the timely development of personalized treatment plans. This technology overcomes the limitations of traditional testing by enabling highly sensitive and accurate detection of minimal residual disease (MRD) in the blood, eliminating the need for bone marrow aspiration. This offers strong support for assessing the risk of multiple myeloma recurrence.

MyeloTrak's product advantages include being non-invasive, painless, highly sensitive, and highly specific. MarkerX's core technology lies in its rigorously efficient, end-to-end process that integrates proteomic analysis, mass spectrometry, and big data modeling. Utilizing our exclusively developed biochemical procedures combined with AI modeling, we precisely analyze M-proteins in the blood—critical indicators of multiple myeloma disease stability—to identify personalized and unique biomarker modules for each patient.

MarkerX's core value is to provide optimal screening technologies for disease prevention, continuously supporting medical teams, and enabling more lives to create infinite value. The launch of MyeloTrak represents another significant milestone for MarkerX in the field of precision medicine.

 

Other Products

 

• 

  AI-Driven Mass Spec Proteomics Platform

 

 

 

Back